Viewing Study NCT02040506

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 10:58 AM
Ignite Modification Date: 2026-03-01 @ 10:05 AM
Study NCT ID: NCT02040506
Status: COMPLETED
Last Update Posted: 2016-02-23
First Post: 2014-01-16
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML
Sponsor: Igenica Biotherapeutics, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Acute Myelogenous Leukemia View
None Acute Myeloid Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Acute Myelogenous Leukemia View
None Acute Myeloid Leukemia View
None Drug therapy View
None CD98 View
None Relapsed View
None Refractory View
None Monoclonal antibody View